Cara Therapeutics reported $0 in Sales Revenues for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Sales Change
Acadia Pharmaceuticals ACAD:US $ 115.22M 8.67M
Acelrx Pharmaceuticals ACRX:US $ 0.44M 0.07M
Aerie Pharmaceuticals AERI:US $ 27.18M 4.22M
Antares Pharma ATRS:US $ 44.98M 2.9M
Arena Pharmaceuticals ARNA:US $ 0M 0M
Biodelivery Sciences International BDSI:US $ 41.44M 0.42M
Cara Therapeutics CARA:US $ 0 1.93M
Chugai Pharma 4519:JP Y 287264M 65853M
Depomed DEPO:US $ 25.37M 1.47M
Endo International Ordinary Shares ENDP:US $ 713.83M 4.09M
Halozyme Therapeutics HALO:US $ 136.46M 47.43M
Horizon Pharma HZNP:US $ 832.55M 490.14M
JAZZ PHA JAZZ:US $ 751.81M 144.23M
Johnson & Johnson JNJ:US $ 23338M 26M
Neurocrine Biosciences NBIX:US $ 288.9M 52.3M
Pacira Pharmaceuticals PCRX:US $ 135.59M 16.56M
Pfizer PFE:US $ 18977M 4395M
Redhill Biopharma RDHL:US $ 21.5M 0.93M
Revance Therapeutics RVNC:US $ 18.8M 5.5M
Supernus Pharmaceuticals SUPN:US $ 141.33M 10.4M
Teva Pharmaceutical Industries TEVA:US $ 3887M 23M
Vanda Pharmaceuticals VNDA:US $ 67.9M 5.23M